Ruxolitinib, a JAK1 and JAK2 inhibitor, has primarily been studied as a topical ointment for mild-to-moderate psoriasis, and it has been compared to other topical therapies, which include topical steroids and topical calcipotriene [19, 40]. This evidence concerns the gene JAK1 and psoriasis.